Oral GLP-1 Medication Aleniglipron Shows Promise for Weight Loss in Clinical Trial
A new oral medication, aleniglipron, has demonstrated significant weight loss in adults with obesity or overweight, according to a randomized phase II clinical trial published in Nature Medicine. The study involved 230 participants across 38 U.S. medical centers, who were randomly assigned to receive either aleniglipron or a placebo over a 36-week period. The results indicated that participants taking aleniglipron lost an average of 12.1% of their body weight, with the most effective dosage being 120 milligrams. In comparison, the placebo group experienced a mere 0.5% weight loss.
Aleniglipron is distinct from existing GLP-1 medications such as semaglutide, which are injectable and peptide-based. As a small-molecule drug, aleniglipron can be taken orally, which may alleviate some barriers associated with injectable treatments, including the need for refrigeration and the complexity of administration. Dr. Robert Kushner, a co-author of the study, emphasized that the oral form of the medication could enhance patient compliance and accessibility.
The trial was designed to evaluate the safety and efficacy of aleniglipron, with participants receiving doses of 45, 90, or 120 milligrams, which were increased every four weeks. By the end of the study, participants in the 120-milligram group had lost an average of 12.1% of their body weight, while those in the 90-milligram and 45-milligram groups lost 10.7% and 9.0%, respectively. The study reported mild to moderate gastrointestinal side effects, which diminished over time, and no significant safety concerns were raised, including no instances of drug-induced liver injury.
Dr. Kushner noted that these positive results support the continued development of aleniglipron as a treatment for obesity, with further evaluations planned in a phase III trial. The findings suggest that aleniglipron could offer a viable alternative for individuals struggling with obesity, particularly those who may have difficulty with injectable options. This research was supported by Structure Therapeutics and highlights the ongoing efforts to improve obesity treatment options.




